FindTrial
Sign In

TIL

BIOLOGICAL7 trials

Sponsors

Sheba Medical Center, Huashan Hospital, Centre Hospitalier Universitaire Vaudois, Tongji Hospital, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Glioblastoma MultiformeMalignant Melanoma Stage IVMetastatic CancerMetastatic MelanomaRecurrence TumorSarcomaSolid TumorSolid Tumor, Adult

Early Phase 1

Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme
NCT03347097
Huashan HospitalGlioblastoma Multiforme
Start: 2017-01-01End: 2021-12-01Target: 40Updated: 2021-08-25

Phase 1

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
CompletedNCT03475134
Centre Hospitalier Universitaire VaudoisMetastatic Melanoma
Start: 2018-02-21End: 2024-06-06Updated: 2025-02-11
Immunotherapy for the Treatment of Advanced Solid Tumor
RecruitingNCT03658785
Tongji HospitalMetastatic Cancer, Recurrence Tumor, Solid Tumor
Start: 2020-04-28End: 2025-12-31Target: 40Updated: 2024-08-13
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
TerminatedNCT03992326
Centre Hospitalier Universitaire VaudoisSolid Tumor, Adult
Start: 2019-09-01End: 2021-03-05Updated: 2021-03-18
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
CompletedNCT04052334
H. Lee Moffitt Cancer Center and Research InstituteSarcoma
Start: 2019-09-27End: 2023-06-16Updated: 2026-02-20
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
Active, not recruitingNCT06961786
TILT Biotherapeutics Ltd.Metastatic Melanoma
Start: 2025-06-25End: 2027-04-01Target: 9Updated: 2026-03-05

Phase 2

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
RecruitingNCT03166397
Sheba Medical CenterMalignant Melanoma Stage IV
Start: 2017-06-05End: 2026-06-01Target: 30Updated: 2023-01-26

Related Papers

Autologous Tumor-Infiltrating Lymphocyte Infusion plus Anti-Programmed Cell Death Protein 1 Therapy to Cure Advanced Hepatocellular Carcinoma following Palliative Hepatectomy
Liver Cancer2025-02-201 citations
Recent Advancements in Cell-Based Therapies in Melanoma.
2024-09-124 citations
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
Journal of Clinical Oncology2023-06-016 citations
5P Tumor microenvironment cellular crosstalk predicts response to adoptive TIL therapy in melanoma patients
Immuno-Oncology Technology2022-12-01
In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.
Journal of Clinical Oncology2021-05-201 citations